Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Buy

Price to Earnings Rating

Sell

Analyst Rating

Buy

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Buy

A

Genmab A/S ADS (GMAB)

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/18/2019

Market Cap

17,132,622,135

Shares Outstanding

66,080,000

Weighted SO

653,224,610

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

ASND --.--%

APLS --.--%

BGNE --.--%

AKRO --.--%

BPMC --.--%

DAWN --.--%

MRTX --.--%

AMLX --.--%

TERN --.--%

Beta

0.8420

Last Div

0.0000

Range

24.53-39.53

Chg

-0.2150

Avg Vol

602104

Mkt Cap

17132622135

Exch

NASDAQ

Country

DK

Phone

45 70 20 27 28

DCF Diff

-21.0169

DCF

50.1769

Div Yield

0.0000

P/S

6.1200

EV Multiple

16.3286

P/FV

0.3806

Div Yield %

0.0000

P/E

2.1421

PEG

0.0545

Payout

0.0000

Current Ratio

5.0268

Quick Ratio

5.0186

Cash Ratio

0.9924

DSO

118.6967

DIO

21.8636

Op Cycle

140.5602

DPO

2064.8918

CCC

-1924.3316

Gross Margin

0.9683

Op Margin

0.3165

Pretax Margin

0.3939

Net Margin

0.2901

Eff Tax Rate

0.2636

ROA

0.1425

ROE

0.1744

ROCE

0.1753

NI/EBT

0.7364

EBT/EBIT

1.2443

EBIT/Rev

0.3165

Debt Ratio

0.0264

D/E

0.0329

LT Debt/Cap

0.0290

Total Debt/Cap

0.0319

Int Coverage

150.1000

CF/Debt

6.6094

Equity Multi

1.2470

Rec Turnover

3.0751

Pay Turnover

0.1768

Inv Turnover

16.6944

FA Turnover

10.0888

Asset Turnover

0.4911

OCF/Share

104.5169

FCF/Share

101.1028

Cash/Share

244.1520

OCF/Sales

0.3551

FCF/OCF

0.9673

CF Coverage

6.6094

ST Coverage

71.6489

CapEx Coverage

30.6136

Div&CapEx Cov

30.6136

P/BV

0.3806

P/B

0.3806

P/S

6.1200

P/E

2.1421

P/FCF

17.8170

P/OCF

1.7499

P/CF

1.7499

PEG

0.0545

P/S

6.1200

EV Multiple

16.3286

P/FV

0.3806

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. May 02, 00:14 Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) GlobeNewswire Inc. Mar 22, 03:29 Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. GlobeNewswire Inc. Dec 08, 00:12 Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) Benzinga Nov 08, 10:00 Analyst Expectations for Genmab's Future

Revenue Product Segmentation